Hydrocodone heart cardiac
The numbers above the bars indicate actual number of hydrocodone heart cardiac suppliers in each year. Avg govt benefit per script 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 In Figure 5.5, there remained a single supplier until the extension expired in 2012.
The price declined during the patent term as volume steadily increased and again when the extended patent expired in 2012 and many additional manufacturers were listed on the PBS. Figure 5.6: PBS Expenditure for Example Drug #3 Drug #3 PBS expenditures 1995 1996 adipex meridia phentermine 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 Year Note: Bars indicate PBS expenditure (excluding the actual values in order to maintain drug anonymity). The numbers above the bars indicate actual number of suppliers in each year. Avg govt benefit per script 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 In Figure 5.6, the first main price decline occurred in 1998 as the number of suppliers increased. This price decline occurred even as volume also declined, although this could be associated with another dosage for this particular drug entering the market during this time (the graph only represents one dosage of the drug). The number of manufacturers increased prior to the original patent term expiry and the price appears to have reached its low in 2009. The volumes shown in these figures do not include 'under-copayment scripts' i.e. The average subsidy per script is also affected by the relative mix of general and concessional subsidies in any one year which was not available in the data hydrocodone heart cardiac used to produce these figures. The figures and discussion above indicate that volume, number of manufacturers and the regulated price reductions are agreement phentermine viagra xanax key factors in the average Government subsidy per script. Patent expiry date can significantly affect the last two of these, though as shown in Figure 5.6, this is not always the case. Cost of extension of term provisions to the PBS At the time that the extension of term provisions were introduced, the estimated additional cost to the PBS was $6 million in 2001-02, increasing to $160 million in 2005-06, due to delays in the introduction of generic products.102This cost was calculated based on delays in the automatic reduction in the Government subsidy that occurs hydrocodone heart cardiac with entry of the first generic drug onto the market.
This cost did not account for the further reductions in PBS expenditure that occur through the Price Disclosure system, discussed in chapter 2. This section considers the potential savings from a reduction to the maximum available length of extensions of term. These calculations are based on a number of assumptions and are provided to give the reader a sense of magnitude. These estimates should be viewed as stylised estimates rather than actual projected savings to the PBS from a change in the extension of term.
Figures used in calculations The total expenditure by the PBS in 2012 was $9.2 billion.103 In any given year, an estimated 2.6% of the total PBS expenditure is on drugs buy tramadol tablets having an extension of term which will expire within the next year104.
Aviane interactions with tramadol
Nl kluis znd phentermine
New tramadol cheap cod online
Oxycodone 5mg acetaminophen 325mg